Abstract:Hutchinson-Gilford progeria syndrome (HGPS or progeria) is typically caused by a dominant-negative C•G-to-T•A mutation (c.1824 C>T; p.G608G) in LMNA, the gene that encodes nuclear lamin A. This mutation causes RNA mis-splicing that produces progerin, a toxic protein that induces rapid ageing and shortens the lifespan of children with progeria to approximately 14 years1-4. Adenine base editors (ABEs) convert targeted A•T base pairs to G•C base pairs with minimal by-products and without requiring double-strand DNA breaks or donor DNA templates5,6. Here we describe the use of an ABE to directly correct the pathogenic HGPS mutation in cultured fibroblasts derived from children with progeria and in a mouse model of HGPS. Lentiviral delivery of the ABE to fibroblasts from children with HGPS resulted in 87-91% correction of the pathogenic allele, mitigation of RNA mis-splicing, reduced levels of progerin and correction of nuclear abnormalities. Unbiased off-target DNA and RNA editing analysis did not detect off-target editing in treated patient-derived fibroblasts. In transgenic mice that are homozygous for the human LMNA c.1824 C>T allele, a single retro-orbital injection of adeno-associated virus 9 (AAV9) encoding the ABE resulted in substantial, durable correction of the pathogenic mutation (around 20-60% across various organs six months after injection), restoration of normal RNA splicing and reduction of progerin protein levels. In vivo base editing rescued the vascular pathology of the mice, preserving vascular smooth muscle cell counts and preventing adventitial fibrosis. A single injection of ABE-expressing AAV9 at postnatal day 14 improved vitality and greatly extended the median lifespan of the mice from 215 to 510 days. These findings demonstrate the potential of in vivo base editing as a possible treatment for HGPS and other genetic diseases by directly correcting their root cause.

In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease

In Vivo Adenine Base Editing Corrects Newborn Murine Model of Hurler Syndrome

In Vivo Base Editing Rescues Hutchinson–Gilford Progeria Syndrome in Mice

ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome

Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells

Cytosine and Adenine Base Editing of the Brain, Liver, Retina, Heart and Skeletal Muscle of Mice Via Adeno-Associated Viruses

Improved specificity and efficacy of base-editing therapies with hybrid guide RNAs

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

Adenine Base Editing in an Adult Mouse Model of Tyrosinaemia

In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model

Amelioration of Metabolic and Behavioral Defects Through Base Editing in the PahR408W Phenylketonuria Mouse Model

Adenine base editor‐based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

Base editing as a genetic treatment for spinal muscular atrophy

Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing

Base editing rescue of spinal muscular atrophy in cells and in mice

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis

ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation

Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice

In vivo prime editing of a metabolic liver disease in mice

Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency